Gossamer Bio (GOSS) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free GOSS Stock Alerts $0.71 -0.03 (-4.06%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGossamer Bio (NASDAQ:GOSS) Earns Outperform Rating from Wedbushmarketbeat.com - April 5 at 8:21 AMGossamer Bio, Inc. (NASDAQ:GOSS) CEO Faheem Hasnain Sells 23,172 Sharesinsidertrades.com - March 29 at 8:56 AMInsider Selling: Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Sells 23,172 Shares of Stockmarketbeat.com - March 28 at 7:55 PMBuy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscapemarkets.businessinsider.com - March 27 at 4:22 PMGossamer Bio (NASDAQ:GOSS) Receives "Overweight" Rating from Piper Sandlermarketbeat.com - March 27 at 1:29 PMGossamer Bio EVP sells over $5,000 in company stockinvesting.com - March 21 at 6:55 PMGossamer Bio executive sells over $5,000 in company stockinvesting.com - March 21 at 6:55 PMAnalysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)markets.businessinsider.com - March 21 at 6:55 PMGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 6.5% in Februarymarketbeat.com - March 18 at 3:57 PMGOSS Apr 2024 1.500 putca.finance.yahoo.com - March 16 at 3:19 PMGOSS Apr 2024 1.000 putfinance.yahoo.com - March 16 at 10:18 AMTara Rae Moss: ‘So many doctors in different continents told me that I would never recover’theguardian.com - March 13 at 12:59 PMGossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directorsfinance.yahoo.com - March 12 at 10:12 AMGossamer Bio Announces Appointment of Steven D. Nathan, M.D.businesswire.com - March 12 at 7:31 AMBarclays Keeps Their Hold Rating on Gossamer Bio (GOSS)markets.businessinsider.com - March 11 at 8:09 AMGossamer Bio, Inc. (NASDAQ:GOSS) to Post FY2026 Earnings of ($0.72) Per Share, Wedbush Forecastsmarketbeat.com - March 8 at 7:22 AMOptimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment Marketmarkets.businessinsider.com - March 7 at 8:58 AMHC Wainwright Research Analysts Lower Earnings Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - March 7 at 7:53 AMGossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansionmarkets.businessinsider.com - March 6 at 7:46 PMGossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Hold" from Analystsmarketbeat.com - March 6 at 1:52 PMGossamer Bio (NASDAQ:GOSS) Given "Outperform" Rating at Wedbushmarketbeat.com - March 6 at 12:17 PMGossamer Bio (NASDAQ:GOSS) Price Target Lowered to $8.00 at The Goldman Sachs Groupmarketbeat.com - March 6 at 12:17 PMGOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023investorplace.com - March 5 at 10:52 PMGossamer Bio (NASDAQ:GOSS) Announces Earnings Resultsmarketbeat.com - March 5 at 11:37 AMGossamer Bio Posts Narrower Loss In Q4 - Quick Factsmarkets.businessinsider.com - March 5 at 9:50 AMGossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Updatebusinesswire.com - March 5 at 7:31 AMArmistice Capital LLC Invests $4.13 Million in Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - March 3 at 10:51 AMPalo Alto Investors LP Purchases 3,065,136 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - March 1 at 10:27 AMARCH Venture Management LLC Takes Position in Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - February 28 at 3:27 PM5,304,212 Shares in Gossamer Bio, Inc. (NASDAQ:GOSS) Acquired by Monashee Investment Management LLCmarketbeat.com - February 25 at 10:47 AMGossamer Bio Stock (NASDAQ:GOSS) Dividends: History, Yield and Datesbenzinga.com - February 22 at 3:34 PMSilverarc Capital Management LLC Makes New $5.11 Million Investment in Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - February 18 at 12:54 PMGossamer Bio Inc (GOSS)investing.com - February 16 at 5:04 PM7 Micro-Cap Stocks That Could Majorly Surprise Investorsfinance.yahoo.com - February 8 at 3:24 AMGossamer Bio Inc.thestreet.com - February 3 at 10:50 PM5 Small-Cap Stocks with High Potentialinsidermonkey.com - January 22 at 2:06 PMPlatinum Investment Management Ltd. Buys 2,994,608 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)marketbeat.com - January 21 at 9:42 AMResearch Analysts Issue Forecasts for Gossamer Bio, Inc.'s Q1 2024 Earnings (NASDAQ:GOSS)marketbeat.com - January 18 at 7:31 AMGossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Rating of "Hold" by Brokeragesmarketbeat.com - January 12 at 2:22 AMFY2023 EPS Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS) Boosted by HC Wainwrightmarketbeat.com - January 10 at 7:26 AMAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Neurogene (NGNE) and Gossamer Bio (GOSS)markets.businessinsider.com - January 8 at 10:09 PMHC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Knowmarkets.businessinsider.com - January 8 at 5:08 PMGossamer Bio (NASDAQ:GOSS) Given New $10.00 Price Target at HC Wainwrightmarketbeat.com - January 8 at 8:24 AMSeralutinib’s Promising Efficacy and Market Potential Reinforce Buy Ratingmarkets.businessinsider.com - December 21 at 10:45 PMGossamer Bio Stock (NASDAQ:GOSS) Insider Tradesbenzinga.com - December 20 at 7:56 PMAnalysts Are Bullish on These Healthcare Stocks: Gossamer Bio (GOSS), Viridian Therapeutics (VRDN)markets.businessinsider.com - December 20 at 12:00 AMGossamer Bio's (GOSS) "Outperform" Rating Reiterated at Wedbushmarketbeat.com - December 19 at 9:14 AMGossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Recommendation of "Hold" by Analystsmarketbeat.com - December 18 at 2:39 AMGossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023finance.yahoo.com - December 13 at 7:56 PMGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - December 5 at 6:52 PM Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now GOSS Media Mentions By Week GOSS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GOSS News Sentiment▼0.000.43▲Average Medical News Sentiment GOSS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GOSS Articles This Week▼02▲GOSS Articles Average Week Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GLSI News Today TRVI News Today VERU News Today CAPR News Today ALIM News Today ME News Today ACET News Today VACC News Today ATOS News Today OGI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GOSS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
